RE:RE:RE:RE:RE:RE:The bones are telling me an 8.00 US offer is coming soon . Our currently approved competitors, Keytruda & Valrubicin, had less than ideal CR rates of 41% & 18%, respectively. A full course of Keytruda to treat high-risk BCG unresponsive NMIBC costs roughly $300K...not to mention its side effects & the need for multiple (every 3 week) doses...up to 35 doses.
The N-803 + BCG combo treatment under Ph 2 study looks promising, but this "intravesical" treatment requires a minimum "21" treatments (induction + maintenance instillations...ouch!). BCG also continues to be in short supply in many parts of the world & there's no "near-term" solution for this shortage at present. It's unclear what the cost of adding N-803 to this potential treatment regimen would be, but my guess is "much higher" than BCG alone ; ).